Mapping the AI Landscape in Life Sciences: A Framework for Evaluation and Adoption
DOI:
https://doi.org/10.30953/bhty.v8.398Keywords:
AI adoption, artificial intelligence, healthcare technology framework, life sciences innovation, pharma AI, pharmaceutical digital transformationAbstract
Background:
Artificial Intelligence (AI) adoption is accelerating in the life sciences sector, offering opportunities to enhance biopharmaceutical research, development, and commercialization. However, the sector lacks structured tools to prioritize AI initiatives across varied business domains.
Objective:
This study presents a framework to categorize and evaluate potential AI applications in the life sciences industry, organizing use cases along two critical dimensions: Phase of Product Lifecycle and Operational Domain.
Methods:
A structured mixed-methods approach was employed, including a modified Delphi consensus process with industry experts, qualitative case study review, and iterative framework refinement between August 2023 and August 2024.
Results:
The resulting matrix framework enables life sciences professionals to assess AI opportunities across research, clinical development, commercialization, and post-marketing activities. Key findings highlight the pervasive nature of AI impact, the emphasis on data-driven strategies, and the regulatory and ethical challenges facing biopharma firms.
Conclusions:
This framework provides a practical model for strategic AI adoption decisions within the life sciences sector and lays the groundwork for future research, policy development, and enterprise transformation efforts.
Downloads
References
Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019 Mar;24(3):773–80.
Gartner [Internet]. [cited 2024 Sep 19]. Understanding Gartner’s Hype Cycles. Available from: https://www.gartner.com/en/documents/3887767
Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018 Oct 10;2(10):719–31.
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019 Jan;25(1):44–56.
Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019 Sep;37(9):1038–40.
Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019 Aug;40(8):577–91.
Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019 Apr 4;380(14):1347–58.
Vayena E, Blasimme A, Cohen IG. Machine learning in medicine: Addressing ethical challenges. PLoS Med. 2018 Nov;15(11):e1002689.
He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. Nat Med. 2019 Jan 7;25(1):30–6.
Lamarre E, Singla A, Sukharevsky A, Zemmel R. A generative AI reset: Rewiring to turn potential into value in 2024 [Internet]. McKinsey & Company; 2024 [cited 2024 Sep 19]. Available from: https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/a-generative-ai-reset-rewiring-to-turn-potential-into-value-in-2024
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Jennifer Hinkel, MSc, Fraser Peck, MBBCh, Cory Kidd, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Blockchain in Healthcare Today (BHTY). Read the full Copyright Statement.
